{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:40:49Z","timestamp":1794811249251,"version":"4.9.1"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK112042"],"award-info":[{"award-number":["R01DK112042"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK106102"],"award-info":[{"award-number":["R01DK106102"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK079337"],"award-info":[{"award-number":["P30DK079337"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL142814"],"award-info":[{"award-number":["R01HL142814"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG061296"],"award-info":[{"award-number":["RF1AG061296"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pflugers Arch - Eur J Physiol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00424-020-02361-w","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T09:30:42Z","timestamp":1583746242000},"page":"1345-1370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["Glucose transporters in the kidney in health and disease"],"prefix":"10.1007","volume":"472","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9211-2063","authenticated-orcid":false,"given":"Volker","family":"Vallon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","first-page":"F859","DOI":"10.1152\/ajprenal.90238.2008","volume":"296","author":"TF Ackermann","year":"2009","unstructured":"Ackermann TF, Boini KM, Volkl H, Bhandaru M, Bareiss PM, Just L, Vallon V, Amann K, Kuhl D, Feng Y, Hammes HP, Lang F (2009) SGK1-sensitive renal tubular glucose reabsorption in diabetes. Am J Physiol Ren Physiol 296:F859\u2013F866. https:\/\/doi.org\/10.1152\/ajprenal.90238.2008","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR2","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1681\/ASN.2006070756","volume":"18","author":"T Ali","year":"2007","unstructured":"Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, Macleod A (2007) Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 18:1292\u20131298. https:\/\/doi.org\/10.1681\/ASN.2006070756","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR3","first-page":"385","volume":"60","author":"SR Ash","year":"1970","unstructured":"Ash SR, Cuppage FE (1970) Shift toward anaerobic glycolysis in the regenerating rat kidney. Am J Pathol 60:385\u2013402","journal-title":"Am J Pathol"},{"key":"2361_CR4","doi-asserted-by":"publisher","first-page":"C475","DOI":"10.1152\/ajpcell.00180.2008","volume":"295","author":"D Balen","year":"2008","unstructured":"Balen D, Ljubojevic M, Breljak D, Brzica H, Zlender V, Koepsell H, Sabolic I (2008) Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Phys Cell Phys 295:C475\u2013C489. https:\/\/doi.org\/10.1152\/ajpcell.00180.2008","journal-title":"Am J Phys Cell Phys"},{"key":"2361_CR5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/ki.2012.67","volume":"81","author":"L Bankir","year":"2012","unstructured":"Bankir L, Yang B (2012) New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism. Kidney Int 81:1179\u20131198. https:\/\/doi.org\/10.1038\/ki.2012.67","journal-title":"Kidney Int"},{"key":"2361_CR6","first-page":"F322","volume":"241","author":"DW Barfuss","year":"1981","unstructured":"Barfuss DW, Schafer JA (1981) Differences in active and passive glucose transport along the proximal nephron. Am J Phys 241:F322\u2013F332","journal-title":"Am J Phys"},{"key":"2361_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369\u2013384. https:\/\/doi.org\/10.1016\/S2213-8587(13)70208-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cphy.c110041","volume":"2","author":"DP Basile","year":"2012","unstructured":"Basile DP, Anderson MD, Sutton TA (2012) Pathophysiology of acute kidney injury. Compr Physiol 2:1303\u20131353. https:\/\/doi.org\/10.1002\/cphy.c110041","journal-title":"Compr Physiol"},{"key":"2361_CR9","first-page":"S206","volume":"12","author":"RC Blantz","year":"1982","unstructured":"Blantz RC, Peterson OW, Gushwa L, Tucker BJ (1982) Effect of modest hyperglycemia on tubuloglomerular feedback activity. Kidney Int Suppl 12:S206\u2013S212","journal-title":"Kidney Int Suppl"},{"key":"2361_CR10","doi-asserted-by":"crossref","unstructured":"van Bommel EJ, Muskiet MH, van Baar MJB (2019) Dapagliflozin reduces measured GFR by reducing renal efferent arteriolar resistance in type 2 diabetes. Diabetes American Diabetes Association 79th scientific sessions:S-157 (abstract)","DOI":"10.2337\/db19-243-OR"},{"key":"2361_CR11","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1172\/JCI45161","volume":"121","author":"JV Bonventre","year":"2011","unstructured":"Bonventre JV, Yang L (2011) Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121:4210\u20134221. https:\/\/doi.org\/10.1172\/JCI45161","journal-title":"J Clin Invest"},{"key":"2361_CR12","doi-asserted-by":"publisher","first-page":"F246","DOI":"10.1152\/ajprenal.1978.235.3.F246","volume":"235","author":"HB Burch","year":"1978","unstructured":"Burch HB, Narins RG, Chu C, Fagioli S, Choi S, McCarthy W, Lowry OH (1978) Distribution along the rat nephron of three enzymes of gluconeogenesis in acidosis and starvation. Am J Phys 235:F246\u2013F253. https:\/\/doi.org\/10.1152\/ajprenal.1978.235.3.F246","journal-title":"Am J Phys"},{"key":"2361_CR13","doi-asserted-by":"publisher","unstructured":"Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de ZD, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW (2019) Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044359","DOI":"10.1161\/CIRCULATIONAHA.119.044359"},{"key":"2361_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A (2019) Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol 18:20. https:\/\/doi.org\/10.1186\/s12933-019-0828-y","journal-title":"Cardiovasc Diabetol"},{"key":"2361_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ekir.2017.06.020","volume":"2","author":"H Chen","year":"2017","unstructured":"Chen H, Busse LW (2017) Novel therapies for acute kidney injury. Kidney Int Rep 2:785\u2013799. https:\/\/doi.org\/10.1016\/j.ekir.2017.06.020","journal-title":"Kidney Int Rep"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1:57\u201392. https:\/\/doi.org\/10.1007\/s13300-010-0006-4","journal-title":"Diabetes Ther"},{"key":"2361_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatte M (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587\u2013597. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005081","journal-title":"Circulation"},{"key":"2361_CR18","doi-asserted-by":"publisher","unstructured":"Chin E, Zhou J, Bondy C (1993) Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. J Clin Invest 91:1810-1815. doi:https:\/\/doi.org\/10.1172\/JCI116392 [doi]","DOI":"10.1172\/JCI116392"},{"key":"2361_CR19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1210\/endo.138.3.5015","volume":"138","author":"E Chin","year":"1997","unstructured":"Chin E, Zamah AM, Landau D, Gronbcek H, Flyvbjerg A, LeRoith D, Bondy CA (1997) Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology 138:1267\u20131275","journal-title":"Endocrinology"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bdd.1909","volume":"35","author":"Y Chino","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi JI, Nakanishi T, Tamai I (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391\u2013404. https:\/\/doi.org\/10.1002\/bdd.1909","journal-title":"Biopharm Drug Dispos"},{"key":"2361_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1681\/ASN.2015111282","volume":"28","author":"MJ Coady","year":"2017","unstructured":"Coady MJ, El TA, Santer R, Bissonnette P, Sasseville LJ, Calado J, Lussier Y, Dumayne C, Bichet DG, Lapointe JY (2017) MAP17 is a necessary activator of renal Na+\/glucose cotransporter SGLT2. J Am Soc Nephrol 28:85\u201393. https:\/\/doi.org\/10.1681\/ASN.2015111282","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/bj3600371","volume":"360","author":"A Conjard","year":"2001","unstructured":"Conjard A, Martin M, Guitton J, Baverel G, Ferrier B (2001) Gluconeogenesis from glutamine and lactate in the isolated human renal proximal tubule: longitudinal heterogeneity and lack of response to adrenaline. Biochem J 360:371\u2013377","journal-title":"Biochem J"},{"key":"2361_CR23","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20:1988\u20131993. https:\/\/doi.org\/10.1111\/dom.13301","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR24","first-page":"F807","volume":"262","author":"JH Dominguez","year":"1992","unstructured":"Dominguez JH, Camp K, Maianu L, Garvey WT (1992) Glucose transporters of rat proximal tubule: differential expression and subcellular distribution. Am J Phys 262:F807\u2013F812","journal-title":"Am J Phys"},{"key":"2361_CR25","first-page":"F283","volume":"266","author":"JH Dominguez","year":"1994","unstructured":"Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT (1994) Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Phys 266:F283\u2013F290","journal-title":"Am J Phys"},{"key":"2361_CR26","first-page":"3","volume":"53","author":"KD Drewnowsk","year":"2002","unstructured":"Drewnowsk KD, Craig MR, Digiovanni SR, McCarty JM, Moorman AF, Lamers WH, Schoolwerth AC (2002) PEPCK mRNA localization in proximal tubule and gene regulation during metabolic acidosis. J Physiol Pharmacol 53:3\u201320","journal-title":"J Physiol Pharmacol"},{"key":"2361_CR27","doi-asserted-by":"publisher","unstructured":"Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Moller M, Jorgensen NR, Faber J, Danser AHJ, Gansevoort RT, Rossing P, Persson F, Heerspink HJL (2019) Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J Clin Med:8. https:\/\/doi.org\/10.3390\/jcm8060779","DOI":"10.3390\/jcm8060779"},{"key":"2361_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00232-005-0743-x","volume":"204","author":"S Eskandari","year":"2005","unstructured":"Eskandari S, Wright EM, Loo DD (2005) Kinetics of the reverse mode of the Na+\/glucose cotransporter. J Membr Biol 204:23\u201332. https:\/\/doi.org\/10.1007\/s00232-005-0743-x","journal-title":"J Membr Biol"},{"key":"2361_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1126\/science.1160406","volume":"321","author":"S Faham","year":"2008","unstructured":"Faham S, Watanabe A, Besserer GM, Cascio D, Specht A, Hirayama BA, Wright EM, Abramson J (2008) The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+\/sugar symport. Science 321:810\u2013814. https:\/\/doi.org\/10.1126\/science.1160406","journal-title":"Science"},{"key":"2361_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1172\/JCI102424","volume":"30","author":"SJ FARBER","year":"1951","unstructured":"FARBER SJ, BERGER EY, EARLE DP (1951) Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125\u2013129. https:\/\/doi.org\/10.1172\/JCI102424","journal-title":"J Clin Invest"},{"key":"2361_CR31","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI74997","volume":"126","author":"NM Farsijani","year":"2016","unstructured":"Farsijani NM, Liu Q, Kobayashi H, Davidoff O, Sha F, Fandrey J, Ikizler TA, O\u2019Connor PM, Haase VH (2016) Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. J Clin Invest 126:1425\u20131437. https:\/\/doi.org\/10.1172\/JCI74997","journal-title":"J Clin Invest"},{"key":"2361_CR32","first-page":"1045","volume":"29","author":"H Fattah","year":"2018","unstructured":"Fattah H, Shigeoka A, Huang W, Patel R, Kasimsetty S, Singh P, McKay DB, Vallon V (2018) Diverse gene expression patterns of renal transporters in AKI. J Am Soc Nephrol 29:1045 (Abstract)","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E (2017) Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26:27\u201338. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.011","journal-title":"Cell Metab"},{"key":"2361_CR34","doi-asserted-by":"publisher","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499-508. doi:72227 https:\/\/doi.org\/10.1172\/JCI72227","DOI":"10.1172\/JCI72227"},{"key":"2361_CR35","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39:1108\u20131114. https:\/\/doi.org\/10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"2361_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000484962","volume":"193","author":"M Fiorentino","year":"2018","unstructured":"Fiorentino M, Grandaliano G, Gesualdo L, Castellano G (2018) Acute kidney injury to chronic kidney disease transition. Contrib Nephrol 193:45\u201354. https:\/\/doi.org\/10.1159\/000484962","journal-title":"Contrib Nephrol"},{"key":"2361_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1479164112441190","volume":"9","author":"C Foote","year":"2012","unstructured":"Foote C, Perkovic V, Neal B (2012) Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 9:117\u2013123. https:\/\/doi.org\/10.1177\/1479164112441190","journal-title":"Diab Vasc Dis Res"},{"key":"2361_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/en.2007-1088","volume":"149","author":"HS Freitas","year":"2008","unstructured":"Freitas HS, Anhe GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF (2008) Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149:717\u2013724. https:\/\/doi.org\/10.1210\/en.2007-1088","journal-title":"Endocrinology"},{"key":"2361_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.mce.2009.02.014","volume":"305","author":"HS Freitas","year":"2009","unstructured":"Freitas HS, Schaan BD, David-Silva A, Sabino-Silva R, Okamoto MM, Alves-Wagner AB, Mori RC, Machado UF (2009) SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1alpha and HNF-3beta. Mol Cell Endocrinol 305:63\u201370. https:\/\/doi.org\/10.1016\/j.mce.2009.02.014","journal-title":"Mol Cell Endocrinol"},{"issue":"supplement 1","key":"2361_CR40","first-page":"A132","volume":"63","author":"Y Fu","year":"2014","unstructured":"Fu Y, Gerasimova M, Mayoux E, Masuda T, Vallon V (2014) SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 63(supplement 1):A132","journal-title":"Diabetes"},{"key":"2361_CR41","doi-asserted-by":"publisher","first-page":"F386","DOI":"10.1152\/ajprenal.00503.2017","volume":"315","author":"Y Fu","year":"2018","unstructured":"Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V (2018) The organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Ren Physiol 315:F386\u2013F394. https:\/\/doi.org\/10.1152\/ajprenal.00503.2017","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR42","doi-asserted-by":"publisher","first-page":"e56681","DOI":"10.1371\/journal.pone.0056681","volume":"8","author":"T Fukuzawa","year":"2013","unstructured":"Fukuzawa T, Fukazawa M, Ueda O, Shimada H, Kito A, Kakefuda M, Kawase Y, Wada NA, Goto C, Fukushima N, Jishage K, Honda K, King GL, Kawabe Y (2013) SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose. PLoS One 8:e56681. https:\/\/doi.org\/10.1371\/journal.pone.0056681","journal-title":"PLoS One"},{"key":"2361_CR43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78\u201389","journal-title":"Diab Vasc Dis Res"},{"key":"2361_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S (2014) Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103:373\u2013381. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.052","journal-title":"Diabetes Res Clin Pract"},{"key":"2361_CR45","doi-asserted-by":"publisher","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","volume":"307","author":"F Gembardt","year":"2014","unstructured":"Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension. Am J Physiol Ren Physiol 307:F317\u2013F325. https:\/\/doi.org\/10.1152\/ajprenal.00145.2014","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR46","doi-asserted-by":"publisher","unstructured":"Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27:136-142. doi:DME2894 [pii];https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02894.x [doi]","DOI":"10.1111\/j.1464-5491.2009.02894.x"},{"key":"2361_CR47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2337\/diacare.24.2.382","volume":"24","author":"JE Gerich","year":"2001","unstructured":"Gerich JE, Meyer C, Woerle HJ, Stumvoll M (2001) Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382\u2013391","journal-title":"Diabetes Care"},{"key":"2361_CR48","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545\u20132559. https:\/\/doi.org\/10.1056\/NEJMoa0802743","journal-title":"N Engl J Med"},{"key":"2361_CR49","doi-asserted-by":"publisher","unstructured":"Ghezzi C, Wright EM (2012) Regulation of the human Na+ dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol 303:C348-C354. doi:ajpcell.00115.2012 [pii];https:\/\/doi.org\/10.1152\/ajpcell.00115.2012 [doi]","DOI":"10.1152\/ajpcell.00115.2012"},{"key":"2361_CR50","doi-asserted-by":"publisher","first-page":"C864","DOI":"10.1152\/ajpcell.00027.2014","volume":"306","author":"C Ghezzi","year":"2014","unstructured":"Ghezzi C, Gorraitz E, Hirayama BA, Loo DD, Grempler R, Mayoux E, Wright EM (2014) Fingerprints of hSGLT5 sugar and cation selectivity. Am J Phys Cell Phys 306:C864\u2013C870. https:\/\/doi.org\/10.1152\/ajpcell.00027.2014","journal-title":"Am J Phys Cell Phys"},{"key":"2361_CR51","doi-asserted-by":"publisher","unstructured":"Ghezzi C, Hirayama BA, Gorraitz E, Loo DD, Liang Y, Wright EM (2014) SGLT2 inhibitors act from the extracellular surface of the cell membrane. Phys Rep 2:pii: e12058. https:\/\/doi.org\/10.14814\/phy2.12058","DOI":"10.14814\/phy2.12058"},{"key":"2361_CR52","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/dom.13754","volume":"21","author":"RE Gilbert","year":"2019","unstructured":"Gilbert RE, Thorpe KE (2019) Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 21:1996\u20132000. https:\/\/doi.org\/10.1111\/dom.13754","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR53","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00125-007-0778-x","volume":"50","author":"AK Goestemeyer","year":"2007","unstructured":"Goestemeyer AK, Marks J, Srai SK, Debnam ES, Unwin RJ (2007) GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration. Diabetologia 50:2209\u20132217. https:\/\/doi.org\/10.1007\/s00125-007-0778-x","journal-title":"Diabetologia"},{"key":"2361_CR54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"V Gorboulev","year":"2012","unstructured":"Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187\u2013196. https:\/\/doi.org\/10.2337\/db11-1029","journal-title":"Diabetes"},{"key":"2361_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.febslet.2011.12.027","volume":"586","author":"R Grempler","year":"2012","unstructured":"Grempler R, Augustin R, Froehner S, Hildebrandt T, Simon E, Mark M, Eickelmann P (2012) Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett 586:248\u2013253. https:\/\/doi.org\/10.1016\/j.febslet.2011.12.027","journal-title":"FEBS Lett"},{"key":"2361_CR56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ki.1984.143","volume":"26","author":"WG Guder","year":"1984","unstructured":"Guder WG, Ross BD (1984) Enzyme distribution along the nephron. Kidney Int 26:101\u2013111","journal-title":"Kidney Int"},{"key":"2361_CR57","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1126\/science.2063193","volume":"252","author":"AC Guyton","year":"1991","unstructured":"Guyton AC (1991) Blood pressure control\u2014special role of the kidneys and body fluids. Science 252:1813\u20131816","journal-title":"Science"},{"key":"2361_CR58","doi-asserted-by":"publisher","first-page":"F819","DOI":"10.1152\/ajprenal.00497.2016","volume":"312","author":"KM Hallow","year":"2017","unstructured":"Hallow KM, Gebremichael Y, Helmlinger G, Vallon V (2017) Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Ren Physiol 312:F819\u2013F835. https:\/\/doi.org\/10.1152\/ajprenal.00497.2016","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR59","doi-asserted-by":"publisher","first-page":"F988","DOI":"10.1152\/ajprenal.00327.2004","volume":"288","author":"HJ Han","year":"2005","unstructured":"Han HJ, Lee YJ, Park SH, Lee JH, Taub M (2005) High glucose-induced oxidative stress inhibits Na+\/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Ren Physiol 288:F988\u2013F996. https:\/\/doi.org\/10.1152\/ajprenal.00327.2004","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1440-1681.12034","volume":"40","author":"P Hansell","year":"2013","unstructured":"Hansell P, Welch WJ, Blantz RC, Palm F (2013) Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension. Clin Exp Pharmacol Physiol 40:123\u2013137. https:\/\/doi.org\/10.1111\/1440-1681.12034","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2361_CR61","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1124\/jpet.114.213454","volume":"350","author":"HH Hansen","year":"2014","unstructured":"Hansen HH, Jelsing J, Hansen CF, Hansen G, Vrang N, Mark M, Klein T, Mayoux E (2014) The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J Pharmacol Exp Ther 350:657\u2013664. https:\/\/doi.org\/10.1124\/jpet.114.213454","journal-title":"J Pharmacol Exp Ther"},{"key":"2361_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/330379a0","volume":"330","author":"MA Hediger","year":"1987","unstructured":"Hediger MA, Coady MJ, Ikeda TS, Wright EM (1987) Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter. Nature 330:379\u2013381. https:\/\/doi.org\/10.1038\/330379a0","journal-title":"Nature"},{"key":"2361_CR63","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","volume":"28","author":"HJ Heerspink","year":"2018","unstructured":"Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V (2018) Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28:368\u2013375. https:\/\/doi.org\/10.1681\/ASN.2016030278","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR64","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15:613\u2013621. https:\/\/doi.org\/10.1111\/dom.12073","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR65","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000170341","volume":"15","author":"SN Heyman","year":"1997","unstructured":"Heyman SN, Rosen S, Brezis M (1997) The renal medulla: life at the edge of anoxia. Blood Purif 15:232\u2013242. https:\/\/doi.org\/10.1159\/000170341","journal-title":"Blood Purif"},{"key":"2361_CR66","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1681\/ASN.2017040371","volume":"29","author":"L Hinden","year":"2018","unstructured":"Hinden L, Udi S, Drori A, Gammal A, Nemirovski A, Hadar R, Baraghithy S, Permyakova A, Geron M, Cohen M, Tsytkin-Kirschenzweig S, Riahi Y, Leibowitz G, Nahmias Y, Priel A, Tam J (2018) Modulation of renal GLUT2 by the cannabinoid-1 receptor: implications for the treatment of diabetic nephropathy. J Am Soc Nephrol 29:434\u2013448. https:\/\/doi.org\/10.1681\/ASN.2017040371","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR67","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, D. dZ, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282\u2013287. https:\/\/doi.org\/10.1038\/ki.2011.79","journal-title":"Kidney Int"},{"key":"2361_CR68","doi-asserted-by":"crossref","unstructured":"Huang W, Patel R, Onishi A, Crespo-Masip M, Soleimani M, Freeman B, Vallon V (2018) Tubular NHE3 is a determinant of the acute natriuretic and chronic blood pressure lowering effect of the SGLT2 inhibitor empagliflozin. FASEB J 32, supplement no 1:620.617","DOI":"10.1096\/fasebj.2018.32.1_supplement.620.17"},{"key":"2361_CR69","doi-asserted-by":"publisher","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","volume":"300","author":"CS Hummel","year":"2011","unstructured":"Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2. Am J Phys Cell Phys 300:C14\u2013C21. https:\/\/doi.org\/10.1152\/ajpcell.00388.2010","journal-title":"Am J Phys Cell Phys"},{"key":"2361_CR70","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1152\/ajpregu.00127.2011","volume":"302","author":"BH Inoue","year":"2012","unstructured":"Inoue BH, dos SL, Pessoa TD, Antonio EL, Pacheco BP, Savignano FA, Carraro-Lacroix LR, Tucci PJ, Malnic G, Girardi AC (2012) Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am J Phys Regul Integr Comp Phys 302:R166\u2013R174. https:\/\/doi.org\/10.1152\/ajpregu.00127.2011","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"2361_CR71","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356\u2013363. https:\/\/doi.org\/10.2337\/dc17-1096","journal-title":"Diabetes Care"},{"key":"2361_CR72","first-page":"333","volume-title":"The juxtaglomerular apparatus","author":"PK Jensen","year":"1988","unstructured":"Jensen PK, Kristensen KS, Rasch R, Persson AEG (1988) Decreased sensitivity of the tubuloglomerular feedback mechanism in experimental diabetic rats. In: Persson AEG, Boberg U (eds) The juxtaglomerular apparatus. Elsevier, Amsterdam, pp 333\u2013338"},{"key":"2361_CR73","first-page":"F159","volume":"246","author":"PA Johnston","year":"1984","unstructured":"Johnston PA, Rennke H, Levinsky NG (1984) Recovery of proximal tubular function from ischemic injury. Am J Phys 246:F159\u2013F166","journal-title":"Am J Phys"},{"key":"2361_CR74","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, Whaley JM, Shulman GI, Kibbey RG (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60:890\u2013898. https:\/\/doi.org\/10.2337\/db10-1328","journal-title":"Diabetes"},{"key":"2361_CR75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.V86943","volume":"8","author":"M Kamran","year":"1997","unstructured":"Kamran M, Peterson RG, Dominguez JH (1997) Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8:943\u2013948","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR76","doi-asserted-by":"crossref","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest, 10.1172\/JCI116972 93:397\u2013404","DOI":"10.1172\/JCI116972"},{"key":"2361_CR77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2015.11.026","volume":"29","author":"M Kanbay","year":"2016","unstructured":"Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, Lanaspa MA, Nakagawa T, Johnson RJ (2016) Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 29:3\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2015.11.026","journal-title":"Eur J Intern Med"},{"key":"2361_CR78","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528\u20132536. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040130","journal-title":"Circulation"},{"key":"2361_CR79","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.nutr.28.061807.155518","volume":"28","author":"GL Kellett","year":"2008","unstructured":"Kellett GL, Brot-Laroche E, Mace OJ, Leturque A (2008) Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr 28:35\u201354. https:\/\/doi.org\/10.1146\/annurev.nutr.28.061807.155518","journal-title":"Annu Rev Nutr"},{"key":"2361_CR80","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/dc14-0920","volume":"38","author":"K Khunti","year":"2015","unstructured":"Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK (2015) Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38:316\u2013322. https:\/\/doi.org\/10.2337\/dc14-0920","journal-title":"Diabetes Care"},{"key":"2361_CR81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.1981.100","volume":"20","author":"KL Klein","year":"1981","unstructured":"Klein KL, Wang MS, Torikai S, Davidson WD, Kurokawa K (1981) Substrate oxidation by isolated single nephron segments of the rat. Kidney Int 20:29\u201335","journal-title":"Kidney Int"},{"key":"2361_CR82","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40620-016-0261-1","volume":"29","author":"DE Kohan","year":"2016","unstructured":"Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L (2016) The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 29:391\u2013400. https:\/\/doi.org\/10.1007\/s40620-016-0261-1","journal-title":"J Nephrol"},{"key":"2361_CR83","doi-asserted-by":"crossref","first-page":"F573","DOI":"10.1152\/ajprenal.2000.279.3.F573","volume":"279","author":"R Komers","year":"2000","unstructured":"Komers R, Lindsley JN, Oyama TT, Allison KM, Anderson S (2000) Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am J Physiol Ren Physiol 279:F573\u2013F583","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR84","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520\u2013526. https:\/\/doi.org\/10.1038\/clpt.2008.251","journal-title":"Clin Pharmacol Ther"},{"key":"2361_CR85","doi-asserted-by":"publisher","first-page":"E859","DOI":"10.1152\/ajpendo.00165.2014","volume":"307","author":"GM Kowalski","year":"2014","unstructured":"Kowalski GM, Bruce CR (2014) The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab 307:E859\u2013E871. https:\/\/doi.org\/10.1152\/ajpendo.00165.2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2361_CR86","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00125-019-4849-6","volume":"62","author":"RE Kuhre","year":"2019","unstructured":"Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, Chen L, Mandrup-Poulsen T, Orskov C, Gribble FM, Reimann F, Wierup N, Tyrberg B, Holst JJ (2019) No direct effect of SGLT2 activity on glucagon secretion. Diabetologia 62:1011\u20131023. https:\/\/doi.org\/10.1007\/s00125-019-4849-6","journal-title":"Diabetologia"},{"key":"2361_CR87","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de ZD, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853\u2013862. https:\/\/doi.org\/10.1111\/dom.12127","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR88","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1681\/ASN.2015020177","volume":"27","author":"R Lan","year":"2016","unstructured":"Lan R, Geng H, Singha PK, Saikumar P, Bottinger EP, Weinberg JM, Venkatachalam MA (2016) Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. J Am Soc Nephrol 27:3356\u20133367. https:\/\/doi.org\/10.1681\/ASN.2015020177","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR89","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1517\/14728220903260807","volume":"13","author":"F Lang","year":"2009","unstructured":"Lang F, Gorlach A, Vallon V (2009) Targeting SGK1 in diabetes. Expert Opin Ther Targets 13:1303\u20131311. https:\/\/doi.org\/10.1517\/14728220903260807","journal-title":"Expert Opin Ther Targets"},{"key":"2361_CR90","doi-asserted-by":"publisher","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","volume":"314","author":"AT Layton","year":"2018","unstructured":"Layton AT, Vallon V (2018) SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Ren Physiol 314:F969\u2013F984. https:\/\/doi.org\/10.1152\/ajprenal.00551.2017","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR91","doi-asserted-by":"publisher","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","volume":"308","author":"AT Layton","year":"2015","unstructured":"Layton AT, Vallon V, Edwards A (2015) Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Ren Physiol 308:F1343\u2013F1357. https:\/\/doi.org\/10.1152\/ajprenal.00007.2015","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR92","doi-asserted-by":"publisher","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","volume":"310","author":"AT Layton","year":"2016","unstructured":"Layton AT, Vallon V, Edwards A (2016) Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Ren Physiol 310:F1269\u2013F1283. https:\/\/doi.org\/10.1152\/ajprenal.00543.2015","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR93","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1016\/S0021-9258(17)32677-7","volume":"269","author":"WS Lee","year":"1994","unstructured":"Lee WS, Kanai Y, Wells RG, Hediger MA (1994) The high affinity Na+\/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269:12032\u201312039","journal-title":"J Biol Chem"},{"key":"2361_CR94","doi-asserted-by":"publisher","unstructured":"Li Z, Agrawal V, Ramratnam M, Sharma RK, D\u2019Auria S, Sincoular A, Jakubiak M, Music ML, Kutschke WJ, Huang XN, Gifford L, Ahmad F (2019) Cardiac sodium-glucose co-transporter 1 (SGLT1) is a novel mediator of ischemia\/reperfusion injury. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvz037","DOI":"10.1093\/cvr\/cvz037"},{"key":"2361_CR95","doi-asserted-by":"publisher","first-page":"F205","DOI":"10.1152\/ajprenal.00237.2004","volume":"290","author":"KC Linden","year":"2006","unstructured":"Linden KC, DeHaan CL, Zhang Y, Glowacka S, Cox AJ, Kelly DJ, Rogers S (2006) Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Ren Physiol 290:F205\u2013F213. https:\/\/doi.org\/10.1152\/ajprenal.00237.2004","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR96","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1523-1755.2005.00282.x","volume":"67","author":"R Liu","year":"2005","unstructured":"Liu R, Carretero OA, Ren Y, Garvin JL (2005) Increased intracellular pH at the macula densa activates nNOS during tubuloglomerular feedback. Kidney Int 67:1837\u20131843. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00282.x","journal-title":"Kidney Int"},{"key":"2361_CR97","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00263.2017","volume":"314","author":"MR Lynch","year":"2018","unstructured":"Lynch MR, Tran MT, Parikh SM (2018) PGC1alpha in the kidney. Am J Physiol Ren Physiol 314:F1\u2013F8. https:\/\/doi.org\/10.1152\/ajprenal.00263.2017","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR98","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","volume":"308","author":"Y Lytvyn","year":"2015","unstructured":"Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ (2015) Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Ren Physiol 308:F77\u2013F83. https:\/\/doi.org\/10.1152\/ajprenal.00555.2014","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR99","doi-asserted-by":"publisher","unstructured":"Lytvyn Y, Bjornstad P, Katz A, Singh SK, Godoy LC, Chung LT, Vinovskis CL, Pyle L, Roussel R, Perkins BA, Cherney D (2019) SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes Metab. https:\/\/doi.org\/10.1016\/j.diabet.2019.11.006","DOI":"10.1016\/j.diabet.2019.11.006"},{"key":"2361_CR100","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1463-1326.2010.01291.x","volume":"12","author":"FR Macdonald","year":"2010","unstructured":"Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, Poucher SM (2010) The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 12:1004\u20131012. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01291.x","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR101","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00424-017-2056-1","volume":"469","author":"IV Madunic","year":"2017","unstructured":"Madunic IV, Breljak D, Karaica D, Koepsell H, Sabolic I (2017) Expression profiling and immunolocalization of Na(+)-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats. Pflugers Arch 469:1545\u20131565. https:\/\/doi.org\/10.1007\/s00424-017-2056-1","journal-title":"Pflugers Arch"},{"key":"2361_CR102","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","volume":"52","author":"GM Magee","year":"2009","unstructured":"Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691\u2013697. https:\/\/doi.org\/10.1007\/s00125-009-1268-0","journal-title":"Diabetologia"},{"key":"2361_CR103","doi-asserted-by":"publisher","unstructured":"Malek M, Nematbakhsh M (2015) Renal ischemia\/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 4:20-27. doi:https:\/\/doi.org\/10.12861\/jrip.2015.06 [doi]","DOI":"10.12861\/jrip.2015.06"},{"key":"2361_CR104","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1113\/jphysiol.2003.046268","volume":"553","author":"J Marks","year":"2003","unstructured":"Marks J, Carvou NJ, Debnam ES, Srai SK, Unwin RJ (2003) Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 553:137\u2013145. https:\/\/doi.org\/10.1113\/jphysiol.2003.046268","journal-title":"J Physiol"},{"key":"2361_CR105","doi-asserted-by":"publisher","unstructured":"Martin MG, Turk E, Lostao MP, Kerner C, Wright EM (1996) Defects in Na+\/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12:216-220. doi:https:\/\/doi.org\/10.1038\/ng0296-216 [doi]","DOI":"10.1038\/ng0296-216"},{"key":"2361_CR106","doi-asserted-by":"publisher","first-page":"F653","DOI":"10.1152\/ajprenal.00143.2018","volume":"315","author":"T Masuda","year":"2018","unstructured":"Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, Imai T, Koepsell H, Muto S, Vallon V, Nagata D (2018) Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Ren Physiol 315:F653\u2013F664. https:\/\/doi.org\/10.1152\/ajprenal.00143.2018","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR107","doi-asserted-by":"publisher","unstructured":"Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, Vallon V, Nagata D (2020) Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep 8:e14360. doi:https:\/\/doi.org\/10.14814\/phy2.14360","DOI":"10.14814\/phy2.14360"},{"key":"2361_CR108","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"2361_CR109","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509\u2013514. https:\/\/doi.org\/10.1172\/JCI70704","journal-title":"J Clin Invest"},{"key":"2361_CR110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","volume":"28","author":"CE Mogensen","year":"1971","unstructured":"Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28:101\u2013109","journal-title":"Scand J Clin Lab Invest"},{"key":"2361_CR111","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1172\/JCI113117","volume":"80","author":"BA Molitoris","year":"1987","unstructured":"Molitoris BA, Kinne R (1987) Ischemia induces surface membrane dysfunction. Mechanism of altered Na+-dependent glucose transport. J Clin Invest 80:647\u2013654. https:\/\/doi.org\/10.1172\/JCI113117","journal-title":"J Clin Invest"},{"key":"2361_CR112","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:457\u2013466. https:\/\/doi.org\/10.1111\/dom.12244","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR113","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","volume":"34","author":"M Mueckler","year":"2013","unstructured":"Mueckler M, Thorens B (2013) The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 34:121\u2013138. https:\/\/doi.org\/10.1016\/j.mam.2012.07.001","journal-title":"Mol Asp Med"},{"key":"2361_CR114","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de ZD, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and |Abetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"2361_CR115","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"O Neill","year":"2015","unstructured":"Neill O, Fasching A, Pihl L, Patinha D, Franzen S, Palm F (2015) Acute SGLT inhibition normalizes oxygen tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Ren Physiol 309:F227\u2013F234. https:\/\/doi.org\/10.1152\/ajprenal.00689.2014","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR116","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1042\/CS20171298","volume":"132","author":"J Nespoux","year":"2018","unstructured":"Nespoux J, Vallon V (2018) SGLT2 inhibition and kidney protection. Clin Sci (Lond) 132:1329\u20131339. https:\/\/doi.org\/10.1042\/CS20171298","journal-title":"Clin Sci (Lond)"},{"key":"2361_CR117","doi-asserted-by":"publisher","unstructured":"Nespoux J, Vallon V (2019) Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. https:\/\/doi.org\/10.1097\/MNH.0000000000000584","DOI":"10.1097\/MNH.0000000000000584"},{"key":"2361_CR118","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00607.2019","author":"J Nespoux","year":"2020","unstructured":"Nespoux J, Patel R, Zhang H, Huang W, Freeman B, Sanders PW, Kim YC, Vallon V (2020) Gene knockout of the Na-glucose cotransporter SGLT2 in a murine model of acute kidney injury induced by ischemia-reperfusion. Am J Physiol Ren Physiol. https:\/\/doi.org\/10.1152\/ajprenal.00607.2019","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR119","doi-asserted-by":"crossref","first-page":"F1201","DOI":"10.1152\/ajprenal.00111.2019","volume":"316","author":"J Nespoux","year":"2019","unstructured":"Nespoux J, Patel R, Hudkins KL, Huang W, Freeman B, Kim Y, Koepsell H, Alpers CE, Vallon V (2019) Gene deletion of the Na-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion. Am J Physiol Ren Physiol 316:F1201\u2013F1210","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR120","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2361_CR121","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/dom.13003","volume":"19","author":"L Norton","year":"2017","unstructured":"Norton L, Shannon CE, Fourcaudot M, Hu C, Wang N, Ren W, Song J, Abdul-Ghani M, DeFronzo RA, Ren J, Jia W (2017) Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 19:1322\u20131326. https:\/\/doi.org\/10.1111\/dom.13003","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR122","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","volume":"316","author":"A Novikov","year":"2019","unstructured":"Novikov A, Fu Y, Huang W, Freeman B, Patel R, van GC, Koepsell H, Busslinger M, Onishi A, Nespoux J, Vallon V (2019) SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Ren Physiol 316:F173\u2013F185. https:\/\/doi.org\/10.1152\/ajprenal.00462.2018","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR123","doi-asserted-by":"publisher","first-page":"F419","DOI":"10.1152\/ajprenal.00497.2018","volume":"317","author":"A Onishi","year":"2019","unstructured":"Onishi A, Fu Y, Darshi M, Crespo-Masip M, Huang W, Song P, Patel R, Kim YC, Nespoux J, Freeman B, Soleimani M, Thomson SC, Sharma K, Vallon V (2019) Effect of renal tubule-specific knockdown of the Na(+)\/H(+) exchanger NHE3 in Akita diabetic mice. Am J Physiol Ren Physiol 317:F419\u2013F434. https:\/\/doi.org\/10.1152\/ajprenal.00497.2018","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR124","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/j.diabres.2009.09.006","volume":"86","author":"H Osorio","year":"2009","unstructured":"Osorio H, Bautista R, Rios A, Franco M, Santamaria J, Escalante B (2009) Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 86:e46\u2013e49. https:\/\/doi.org\/10.1016\/j.diabres.2009.09.006","journal-title":"Diabetes Res Clin Pract"},{"key":"2361_CR125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1530\/eje.0.1500627","volume":"150","author":"JM Pascual","year":"2004","unstructured":"Pascual JM, Wang D, Lecumberri B, Yang H, Mao X, Yang R, De Vivo DC (2004) GLUT1 deficiency and other glucose transporter diseases. Eur J Endocrinol 150:627\u2013633","journal-title":"Eur J Endocrinol"},{"key":"2361_CR126","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2337\/dc13-2338","volume":"37","author":"BA Perkins","year":"2014","unstructured":"Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle HJ, Broedl UC, Johansen OE (2014) Sodium-glucose Cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480\u20131483. https:\/\/doi.org\/10.2337\/dc13-2338","journal-title":"Diabetes Care"},{"key":"2361_CR127","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1185\/03007995.2015.1092128","volume":"31","author":"V Perkovic","year":"2015","unstructured":"Perkovic V, Jardine M, Vijapurkar U, Meininger G (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin 31:2219\u20132231. https:\/\/doi.org\/10.1185\/03007995.2015.1092128","journal-title":"Curr Med Res Opin"},{"key":"2361_CR128","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de ZD, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"2361_CR129","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1681\/ASN.2013060588","volume":"25","author":"TD Pessoa","year":"2014","unstructured":"Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G (2014) Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25:2028\u20132039. https:\/\/doi.org\/10.1681\/ASN.2013060588","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR130","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2215\/CJN.10180916","volume":"12","author":"S Petrykiv","year":"2017","unstructured":"Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson F, Heerspink HJL (2017) Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12:751\u2013759. https:\/\/doi.org\/10.2215\/CJN.10180916","journal-title":"Clin J Am Soc Nephrol"},{"key":"2361_CR131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000066789","volume":"25","author":"IL Pfaff","year":"2002","unstructured":"Pfaff IL, Vallon V (2002) Protein kinase C beta isoenzymes in diabetic kidneys and their relation to nephroprotective actions of the ACE inhibitor lisinopril. Kidney Blood Press Res 25:329\u2013340","journal-title":"Kidney Blood Press Res"},{"key":"2361_CR132","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.V1091861","volume":"10","author":"IL Pfaff","year":"1999","unstructured":"Pfaff IL, Wagner HJ, Vallon V (1999) Immunolocalization of protein kinase C isoenzymes alpha, beta1 and betaII in rat kidney. J Am Soc Nephrol 10:1861\u20131873","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR133","first-page":"1101","volume":"150","author":"AO Phillips","year":"1997","unstructured":"Phillips AO, Steadman R, Morrisey K, Williams JD (1997) Polarity of stimulation and secretion of transforming growth factor-beta 1 by cultured proximal tubular cells. Am J Pathol 150:1101\u20131111","journal-title":"Am J Pathol"},{"key":"2361_CR134","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","volume":"304","author":"DR Powell","year":"2013","unstructured":"Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304:E117\u2013E130. https:\/\/doi.org\/10.1152\/ajpendo.00439.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2361_CR135","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.114.214304","volume":"350","author":"DR Powell","year":"2014","unstructured":"Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, Mseeh F, Wilson A, Shadoan M, Zambrowicz B, Ding ZM (2014) Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther 350:232\u2013242. https:\/\/doi.org\/10.1124\/jpet.114.214304","journal-title":"J Pharmacol Exp Ther"},{"key":"2361_CR136","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.kint.2017.10.020","volume":"93","author":"M Pruijm","year":"2018","unstructured":"Pruijm M, Milani B, Pivin E, Podhajska A, Vogt B, Stuber M, Burnier M (2018) Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney Int 93:932\u2013940. https:\/\/doi.org\/10.1016\/j.kint.2017.10.020","journal-title":"Kidney Int"},{"key":"2361_CR137","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/dmrr.2886","volume":"33","author":"H Qiu","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V (2017) Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 33:5. https:\/\/doi.org\/10.1002\/dmrr.2886","journal-title":"Diabetes Metab Res Rev"},{"key":"2361_CR138","doi-asserted-by":"crossref","first-page":"F151","DOI":"10.1152\/ajpcell.1987.253.1.C151","volume":"253","author":"GA Quamme","year":"1987","unstructured":"Quamme GA, Freeman HJ (1987) Evidence for a high-affinity sodium-dependent D-glucose transport system in the kidney. Am J Phys 253:F151\u2013F157","journal-title":"Am J Phys"},{"key":"2361_CR139","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/156800805774912962","volume":"5","author":"PG Quinn","year":"2005","unstructured":"Quinn PG, Yeagley D (2005) Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 5:423\u2013437","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"2361_CR140","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427\u20133434","journal-title":"Diabetes"},{"key":"2361_CR141","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V (2018) Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61:2079\u20132086. https:\/\/doi.org\/10.1007\/s00125-018-4654-7","journal-title":"Diabetologia"},{"key":"2361_CR142","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Ren Physiol 306:F188\u2013F193. https:\/\/doi.org\/10.1152\/ajprenal.00518.2013","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR143","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/08860229209106636","volume":"14","author":"S Rosen","year":"1992","unstructured":"Rosen S, Epstein FH, Brezis M (1992) Determinants of intrarenal oxygenation: factors in acute renal failure. Ren Fail 14:321\u2013325","journal-title":"Ren Fail"},{"key":"2361_CR144","doi-asserted-by":"publisher","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","volume":"302","author":"I Sabolic","year":"2012","unstructured":"Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H (2012) Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302:C1174\u2013C1188. https:\/\/doi.org\/10.1152\/ajpcell.00450.2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"2361_CR145","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1113\/JP271904","volume":"594","author":"M Sala-Rabanal","year":"2016","unstructured":"Sala-Rabanal M, Hirayama BA, Ghezzi C, Liu J, Huang SC, Kepe V, Koepsell H, Yu A, Powell DR, Thorens B, Wright EM, Barrio JR (2016) Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. J Physiol 594:4425\u20134438. https:\/\/doi.org\/10.1113\/JP271904","journal-title":"J Physiol"},{"key":"2361_CR146","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","volume":"8","author":"M Sano","year":"2016","unstructured":"Sano M, Takei M, Shiraishi Y, Suzuki Y (2016) Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8:844\u2013847. https:\/\/doi.org\/10.14740\/jocmr2760w","journal-title":"J Clin Med Res"},{"key":"2361_CR147","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.04010609","volume":"5","author":"R Santer","year":"2010","unstructured":"Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133\u2013141. https:\/\/doi.org\/10.2215\/CJN.04010609","journal-title":"Clin J Am Soc Nephrol"},{"key":"2361_CR148","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s004310050937","volume":"157","author":"R Santer","year":"1998","unstructured":"Santer R, Schneppenheim R, Suter D, Schaub J, Steinmann B (1998) Fanconi-Bickel syndrome\u2014the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur J Pediatr 157:783\u2013797","journal-title":"Eur J Pediatr"},{"key":"2361_CR149","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00439-001-0638-6","volume":"110","author":"R Santer","year":"2002","unstructured":"Santer R, Groth S, Kinner M, Dombrowski A, Berry GT, Brodehl J, Leonard JV, Moses S, Norgren S, Skovby F, Schneppenheim R, Steinmann B, Schaub J (2002) The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet 110:21\u201329. https:\/\/doi.org\/10.1007\/s00439-001-0638-6","journal-title":"Hum Genet"},{"key":"2361_CR150","doi-asserted-by":"publisher","unstructured":"Saponaro C, Muhlemann M, Acosta-Montalvo A, Piron A, Gmyr V, Delalleau N, Moerman E, Thevenet J, Pasquetti G, Coddeville A, Cnop M, Kerr-Conte J, Staels B, Pattou F, Bonner C (2020) Inter-individual heterogeneity of SGLT2 expression and function in human pancreatic islets. Diabetes. https:\/\/doi.org\/10.2337\/db19-0888","DOI":"10.2337\/db19-0888"},{"key":"2361_CR151","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.2337\/db16-1602","volume":"66","author":"M Sasaki","year":"2017","unstructured":"Sasaki M, Sasako T, Kubota N, Sakurai Y, Takamoto I, Kubota T, Inagi R, Seki G, Goto M, Ueki K, Nangaku M, Jomori T, Kadowaki T (2017) Dual regulation of gluconeogenesis by insulin and glucose in the proximal tubules of the kidney. Diabetes 66:2339\u20132350. https:\/\/doi.org\/10.2337\/db16-1602","journal-title":"Diabetes"},{"key":"2361_CR152","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/ckj\/sfy122","volume":"12","author":"B Satirapoj","year":"2019","unstructured":"Satirapoj B, Korkiatpitak P, Supasyndh O (2019) Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial. Clin Kidney J 12:326\u2013332. https:\/\/doi.org\/10.1093\/ckj\/sfy122","journal-title":"Clin Kidney J"},{"key":"2361_CR153","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1681\/ASN.2006050454","volume":"18","author":"C Schmidt","year":"2007","unstructured":"Schmidt C, Hocherl K, Schweda F, Kurtz A, Bucher M (2007) Regulation of renal sodium transporters during severe inflammation. J Am Soc Nephrol 18:1072\u20131083. https:\/\/doi.org\/10.1681\/ASN.2006050454","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR154","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/ng0298-188","volume":"18","author":"G Seidner","year":"1998","unstructured":"Seidner G, Alvarez MG, Yeh JI, O\u2019Driscoll KR, Klepper J, Stump TS, Wang D, Spinner NB, Birnbaum MJ, De Vivo DC (1998) GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 18:188\u2013191. https:\/\/doi.org\/10.1038\/ng0298-188","journal-title":"Nat Genet"},{"key":"2361_CR155","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669\u2013672. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01406.x","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR156","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/ki.1986.103","volume":"29","author":"PF Shanley","year":"1986","unstructured":"Shanley PF, Brezis M, Spokes K, Silva P, Epstein FH, Rosen S (1986) Transport-dependent cell injury in the S3 segment of the proximal tubule. Kidney Int 29:1033\u20131037","journal-title":"Kidney Int"},{"key":"2361_CR157","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1152\/ajprenal.00046.2017","volume":"313","author":"BD Shepard","year":"2017","unstructured":"Shepard BD, Pluznick JL (2017) Saving the sweetness: renal glucose handling in health and disease. Am J Physiol Ren Physiol 313:F55\u2013F61. https:\/\/doi.org\/10.1152\/ajprenal.00046.2017","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR158","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/dme.13645","volume":"35","author":"H Sims","year":"2018","unstructured":"Sims H, Smith KH, Bramlage P, Minguet J (2018) Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of type 1 and type 2 diabetes mellitus. Diabet Med 35:1037\u20131048. https:\/\/doi.org\/10.1111\/dme.13645","journal-title":"Diabet Med"},{"key":"2361_CR159","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/dom.12970","volume":"19","author":"A Solini","year":"2017","unstructured":"Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E (2017) Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 19:1289\u20131294. https:\/\/doi.org\/10.1111\/dom.12970","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR160","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","volume":"20","author":"P Song","year":"2016","unstructured":"Song P, Onishi A, Koepsell H, Vallon V (2016) Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets 20:1109\u20131125. https:\/\/doi.org\/10.1517\/14728222.2016.1168808","journal-title":"Expert Opin Ther Targets"},{"key":"2361_CR161","doi-asserted-by":"crossref","first-page":"F207","DOI":"10.1152\/ajprenal.00120.2019","volume":"317","author":"P Song","year":"2019","unstructured":"Song P, Huang W, Onishi A, Patel R, Kim Y, van Ginkel C, Fu Y, Freeman B, Koepsell H, Thomson SC, Liu R, Vallon V (2019) Knockout of Na-glucose-cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase-1 in macula densa and glomerular hyperfiltration. Am J Physiol Ren Physiol 317:F207\u2013F217","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR162","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1113\/EP086042","volume":"102","author":"M Sotak","year":"2017","unstructured":"Sotak M, Marks J, Unwin RJ (2017) Putative tissue location and function of the SLC5 family member SGLT3. Exp Physiol 102:5\u201313. https:\/\/doi.org\/10.1113\/EP086042","journal-title":"Exp Physiol"},{"key":"2361_CR163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","volume":"19","author":"T Suga","year":"2019","unstructured":"Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, Kohno D, Sasaki T, Takeuchi K, Kakizaki S, Yamada M, Kitamura T (2019) SGLT1 in pancreatic alpha cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab 19:1\u201312. https:\/\/doi.org\/10.1016\/j.molmet.2018.10.009","journal-title":"Mol Metab"},{"key":"2361_CR164","doi-asserted-by":"publisher","unstructured":"Sugawara-Yokoo M, Suzuki T, Matsuzaki T, Naruse T, Takata K (1999) Presence of fructose transporter GLUT5 in the S3 proximal tubules in the rat kidney. Kidney Int 56:1022-1028. doi:S0085-2538(15)46380-X [pii];https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00635.x [doi]","DOI":"10.1046\/j.1523-1755.1999.00635.x"},{"key":"2361_CR165","doi-asserted-by":"publisher","unstructured":"Swe MT, Pongchaidecha A, Chatsudthipong V, Chattipakorn N, Lungkaphin A (2019) Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions. J Cell Physiol 234:8134-8151. doi:https:\/\/doi.org\/10.1002\/jcp.27598 [doi]","DOI":"10.1002\/jcp.27598"},{"key":"2361_CR166","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12929-017-0371-7","volume":"24","author":"L Szablewski","year":"2017","unstructured":"Szablewski L (2017) Distribution of glucose transporters in renal diseases. J Biomed Sci 24:64. https:\/\/doi.org\/10.1186\/s12929-017-0371-7","journal-title":"J Biomed Sci"},{"key":"2361_CR167","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.lfs.2004.10.016","volume":"76","author":"S Tazawa","year":"2005","unstructured":"Tazawa S, Yamato T, Fujikura H, Hiratochi M, Itoh F, Tomae M, Takemura Y, Maruyama H, Sugiyama T, Wakamatsu A, Isogai T, Isaji M (2005) SLC5A9\/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 76:1039\u20131050. https:\/\/doi.org\/10.1016\/j.lfs.2004.10.016","journal-title":"Life Sci"},{"key":"2361_CR168","doi-asserted-by":"publisher","unstructured":"Thomson SC, Vallon V (2019) Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol 124 Suppl 1:S28-S35. https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.027","DOI":"10.1016\/j.amjcard.2019.10.027"},{"key":"2361_CR169","doi-asserted-by":"publisher","first-page":"F732","DOI":"10.1152\/ajprenal.00340.2003","volume":"287","author":"SC Thomson","year":"2004","unstructured":"Thomson SC, Deng A, Komine N, Hammes JS, Blantz RC, Gabbai FB (2004) Early diabetes as a model for testing the regulation of juxtaglomerular NOS I. Am J Physiol Ren Physiol 287:F732\u2013F738. https:\/\/doi.org\/10.1152\/ajprenal.00340.2003","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR170","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","volume":"302","author":"SC Thomson","year":"2012","unstructured":"Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Phys Regul Integr Comp Phys 302:R75\u2013R83. https:\/\/doi.org\/10.1152\/ajpregu.00357.2011","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"2361_CR171","doi-asserted-by":"crossref","first-page":"C286","DOI":"10.1152\/ajpcell.1990.259.2.C286","volume":"259","author":"B Thorens","year":"1990","unstructured":"Thorens B, Lodish HF, Brown D (1990) Differential localization of two glucose transporter isoforms in rat kidney. Am J Phys 259:C286\u2013C294","journal-title":"Am J Phys"},{"key":"2361_CR172","doi-asserted-by":"publisher","first-page":"F974","DOI":"10.1152\/ajprenal.00149.2007","volume":"293","author":"S Tiwari","year":"2007","unstructured":"Tiwari S, Riazi S, Ecelbarger CA (2007) Insulin\u2019s impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Ren Physiol 293:F974\u2013F984. https:\/\/doi.org\/10.1152\/ajprenal.00149.2007","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR173","first-page":"F886","volume":"265","author":"JP Tolins","year":"1993","unstructured":"Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM (1993) Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Phys 265:F886\u2013F895","journal-title":"Am J Phys"},{"key":"2361_CR174","first-page":"F406","volume":"242","author":"RJ Turner","year":"1982","unstructured":"Turner RJ, Moran A (1982) Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Phys 242:F406\u2013F414","journal-title":"Am J Phys"},{"key":"2361_CR175","first-page":"F977","volume":"255","author":"S Uchida","year":"1988","unstructured":"Uchida S, Endou H (1988) Substrate specificity to maintain cellular ATP along the mouse nephron. Am J Phys 255:F977\u2013F983","journal-title":"Am J Phys"},{"key":"2361_CR176","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","volume":"8","author":"H Umino","year":"2018","unstructured":"Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, Tokuyama H, Wakino S, Itoh H (2018) High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep 8:6791. https:\/\/doi.org\/10.1038\/s41598-018-25054-y","journal-title":"Sci Rep"},{"key":"2361_CR177","doi-asserted-by":"publisher","unstructured":"Vaduganathan M, Januzzi JL, Jr. (2019) Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors. Am J Cardiol 124 Suppl 1:S20-S27. https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.026","DOI":"10.1016\/j.amjcard.2019.10.026"},{"key":"2361_CR178","doi-asserted-by":"publisher","first-page":"C6","DOI":"10.1152\/ajpcell.00444.2010","volume":"300","author":"V Vallon","year":"2011","unstructured":"Vallon V (2011) Molecular determinants of renal glucose transport. Am J Phys Cell Phys 300:C6\u2013C8. https:\/\/doi.org\/10.1152\/ajpcell.00444.2010","journal-title":"Am J Phys Cell Phys"},{"key":"2361_CR179","doi-asserted-by":"publisher","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","volume":"300","author":"V Vallon","year":"2011","unstructured":"Vallon V (2011) The proximal tubule in the pathophysiology of the diabetic kidney. Am J Phys Regul Integr Comp Phys 300:R1009\u2013R1022. https:\/\/doi.org\/10.1152\/ajpregu.00809.2010","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"2361_CR180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255\u2013270","journal-title":"Annu Rev Med"},{"key":"2361_CR181","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000446448","volume":"134","author":"V Vallon","year":"2016","unstructured":"Vallon V (2016) Tubular transport in acute kidney injury: relevance for diagnosis, prognosis and intervention. Nephron 134:160\u2013166. https:\/\/doi.org\/10.1159\/000446448","journal-title":"Nephron"},{"key":"2361_CR182","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00169840","volume":"349","author":"V Vallon","year":"1994","unstructured":"Vallon V, Osswald H (1994) Dipyridamole prevents diabetes-induced alterations of kidney function in rats. Naunyn Schmiedeberg's Arch Pharmacol 349:217\u2013222","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"2361_CR183","doi-asserted-by":"crossref","first-page":"F892","DOI":"10.1152\/ajpcell.1995.269.4.C892","volume":"269","author":"V Vallon","year":"1995","unstructured":"Vallon V, Thomson S (1995) Inhibition of local nitric oxide synthase increases homeostatic efficiency of tubuloglomerular feedback. Am J Phys 269:F892\u2013F899","journal-title":"Am J Phys"},{"key":"2361_CR184","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","volume":"74","author":"V Vallon","year":"2012","unstructured":"Vallon V, Thomson SC (2012) Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 74:351\u2013375. https:\/\/doi.org\/10.1146\/annurev-physiol-020911-153333","journal-title":"Annu Rev Physiol"},{"key":"2361_CR185","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215\u2013225. https:\/\/doi.org\/10.1007\/s00125-016-4157-3","journal-title":"Diabetologia"},{"key":"2361_CR186","first-page":"F876","volume":"269","author":"V Vallon","year":"1995","unstructured":"Vallon V, Blantz RC, Thomson S (1995) Homeostatic efficiency of tubuloglomerular feedback is reduced in established diabetes mellitus in rats. Am J Phys 269:F876\u2013F883","journal-title":"Am J Phys"},{"key":"2361_CR187","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","volume":"10","author":"V Vallon","year":"1999","unstructured":"Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569\u20132576","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR188","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1681\/ASN.V12102003","volume":"12","author":"V Vallon","year":"2001","unstructured":"Vallon V, Grahammer F, Richter K, Bleich M, Lang F, Barhanin J, Volkl H, Warth R (2001) Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol 12:2003\u20132011","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR189","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.V1281599","volume":"12","author":"V Vallon","year":"2001","unstructured":"Vallon V, Traynor T, Barajas L, Huang YG, Briggs JP, Schnermann J (2001) Feedback control of glomerular vascular tone in neuronal nitric oxide synthase knockout mice. J Am Soc Nephrol 12:1599\u20131606","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ASN.0000051700.07403.27","volume":"14","author":"V Vallon","year":"2003","unstructured":"Vallon V, Blantz RC, Thomson S (2003) Glomerular hyperfiltration and the salt paradox in early type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 14:530\u2013537","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR191","doi-asserted-by":"publisher","first-page":"17864","DOI":"10.1073\/pnas.0505860102","volume":"102","author":"V Vallon","year":"2005","unstructured":"Vallon V, Grahammer F, Volkl H, Sandu CD, Richter K, Rexhepaj R, Gerlach U, Rong Q, Pfeifer K, Lang F (2005) KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci U S A 102:17864\u201317869. https:\/\/doi.org\/10.1073\/pnas.0505860102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2361_CR192","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","volume":"86","author":"V Vallon","year":"2006","unstructured":"Vallon V, Muhlbauer B, Osswald H (2006) Adenosine and kidney function. Physiol Rev 86:901\u2013940","journal-title":"Physiol Rev"},{"key":"2361_CR193","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104\u2013112","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR194","doi-asserted-by":"publisher","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","volume":"304","author":"V Vallon","year":"2013","unstructured":"Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Ren Physiol 304:F156\u2013F167. https:\/\/doi.org\/10.1152\/ajprenal.00409.2012","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR195","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Ren Physiol 306:F194\u2013F204. https:\/\/doi.org\/10.1152\/ajprenal.00520.2013","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR196","first-page":"218","volume-title":"Brenner & Rector\u2019s the kidney","author":"V Vallon","year":"2020","unstructured":"Vallon V, Broer S, Nigam SK (2020) Renal handling of organic solutes. In: Yu AS, Chertow G, Luyckx V, Marsden PA, Skorecki K, Taal MW (eds) Brenner & Rector\u2019s the kidney, 11th edn. Elsevier, Philadelphia, pp 218\u2013246","edition":"11"},{"key":"2361_CR197","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen ED, Klessen D, Burger C, Breljak D, Kraus O, Radovic N, Jadrijevic S, Aleksic I, Walles T, Sauvant C, Sabolic I, Koepsell H (2015) Localizations of Na-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881\u20131898. https:\/\/doi.org\/10.1007\/s00424-014-1619-7","journal-title":"Pflugers Arch"},{"key":"2361_CR198","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","volume":"292","author":"XX Wang","year":"2017","unstructured":"Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D\u2019Agati VD, Koepsell H, Kopp JB, Rosenberg A, Levi M (2017) SGLT2 expression is increased in human diabetic nephropathy: SGLT2 inhibition decreases renal lipid accumulation, inflammation and the development of nephropathy in diabetic mice. J Biol Chem 292:5335\u20135348. https:\/\/doi.org\/10.1074\/jbc.M117.779520","journal-title":"J Biol Chem"},{"key":"2361_CR199","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von EM, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"2361_CR200","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von EM, Zinman B (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119\u2013129. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028268","journal-title":"Circulation"},{"key":"2361_CR201","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1681\/ASN.2009040419","volume":"20","author":"JM Weinberg","year":"2009","unstructured":"Weinberg JM, Molitoris BA (2009) Illuminating mitochondrial function and dysfunction using multiphoton technology. J Am Soc Nephrol 20:1164\u20131166. https:\/\/doi.org\/10.1681\/ASN.2009040419","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR202","first-page":"F459","volume":"263","author":"RG Wells","year":"1992","unstructured":"Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA (1992) Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Phys 263:F459\u2013F465","journal-title":"Am J Phys"},{"key":"2361_CR203","doi-asserted-by":"crossref","first-page":"11993","DOI":"10.1073\/pnas.89.24.11993","volume":"89","author":"CS Wilcox","year":"1992","unstructured":"Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R, Schmidt HH (1992) Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci U S A 89:11993\u201311997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2361_CR204","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1079\/BJN2002763","volume":"89","author":"IS Wood","year":"2003","unstructured":"Wood IS, Trayhurn P (2003) Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89:3\u20139. https:\/\/doi.org\/10.1079\/BJN2002763","journal-title":"Br J Nutr"},{"key":"2361_CR205","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"EM Wright","year":"2001","unstructured":"Wright EM (2001) Renal Na(+)-glucose cotransporters. Am J Physiol Ren Physiol 280:F10\u2013F18","journal-title":"Am J Physiol Ren Physiol"},{"key":"2361_CR206","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","volume":"34","author":"EM Wright","year":"2013","unstructured":"Wright EM (2013) Glucose transport families SLC5 and SLC50. Mol Asp Med 34:183\u2013196. https:\/\/doi.org\/10.1016\/j.mam.2012.11.002","journal-title":"Mol Asp Med"},{"key":"2361_CR207","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00424-003-1063-6","volume":"447","author":"EM Wright","year":"2004","unstructured":"Wright EM, Turk E (2004) The sodium\/glucose cotransport family SLC5. Pflugers Arch 447:510\u2013518. https:\/\/doi.org\/10.1007\/s00424-003-1063-6","journal-title":"Pflugers Arch"},{"key":"2361_CR208","doi-asserted-by":"publisher","unstructured":"Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733-794. doi:91\/2\/733 [pii];https:\/\/doi.org\/10.1152\/physrev.00055.2009 [doi]","DOI":"10.1152\/physrev.00055.2009"},{"key":"2361_CR209","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"JF Yale","year":"2013","unstructured":"Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463\u2013473. https:\/\/doi.org\/10.1111\/dom.12090","journal-title":"Diabetes Obes Metab"},{"key":"2361_CR210","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","volume":"270","author":"G You","year":"1995","unstructured":"You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK, Hediger MA (1995) Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270:29365\u201329371","journal-title":"J Biol Chem"},{"key":"2361_CR211","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1074\/jbc.M113.526814","volume":"289","author":"JR Zapata-Morales","year":"2014","unstructured":"Zapata-Morales JR, Galicia-Cruz OG, Franco M, Martinez YM (2014) Hypoxia-inducible factor-1alpha (HIF-1alpha) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J Biol Chem 289:346\u2013357. https:\/\/doi.org\/10.1074\/jbc.M113.526814","journal-title":"J Biol Chem"},{"key":"2361_CR212","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"2361_CR213","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","volume":"94","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A (2018) A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94:524\u2013535. https:\/\/doi.org\/10.1016\/j.kint.2018.05.002","journal-title":"Kidney Int"},{"key":"2361_CR214","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2018080844","volume":"30","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wei J, Jiang S, Xu L, Wang L, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R (2019) Macula densa SGLT1-NOS1-TGF pathway\u2014a new mechanism for glomerular hyperfiltration during hyperglycemia. J Am Soc Nephrol 30:578\u2013593","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR215","first-page":"E409","volume":"276","author":"K Zierler","year":"1999","unstructured":"Zierler K (1999) Whole body glucose metabolism. Am J Phys 276:E409\u2013E426","journal-title":"Am J Phys"},{"key":"2361_CR216","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Pfl\u00fcgers Archiv - European Journal of Physiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-020-02361-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00424-020-02361-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-020-02361-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T21:21:28Z","timestamp":1666041688000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00424-020-02361-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":216,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s00424-020-02361-w","relation":{},"ISSN":["0031-6768","1432-2013"],"issn-type":[{"value":"0031-6768","type":"print"},{"value":"1432-2013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"31 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Over the past 36\u00a0months, VV has served as a consultant and received honoraria from Astra-Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceutical, Merck, and Retrophin, and received grant support for investigator-initiated research from Astra-Zeneca, Bayer, Boehringer Ingelheim, Fresenius, Janssen, and Novo-Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}